House committees step up investigation into FDA approval of controversial Alzheimer’s drug

The agency’s June 7 accelerated approval of the medication, the first Alzheimer’s drug cleared in almost two decades, was welcomed by some advocates and doctors as a step forward in treating the devastating disease but strongly criticized by many experts who say the medication hasn’t been shown to be effective. The decision was especially controversial because the agency’s own outside experts had recommended against approval. Some medical centers have refused to offer the drug, which carries a list price of $56,000 a year per patient.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button